Tags : Voluntis

Insights+

PharmaShots’ Key Highlights of Second Quarter 2021

The second quarter of 2021 witnesses major acquisitions, approvals, and clinical data. There are major alliances in this quarter which include Merck signed ~$1.2B supply agreement with US Government for Molnupiravir to treat COVID-19 The big acquisition took place during the quarter including Microsoft acquired Nuance for ~$19.7B, MorphoSys acquired Constellation for ~$1.7B Our team […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Apr 26 – 30, 2021)

BMS Reports the US FDA’s Acceptance of Opdivo’s sBLA for Priority Review to Treat Muscle Invasive Urothelial Carcinoma Published: Apr 30, 2021 | Tags: BMS, US, FDA, Opdivo, sBLA, Priority Review, nivolumab, Muscle Invasive Urothelial Carcinoma Janssen Reports MAA Submission to EMA for Cilta-cel to Treat Relapsed/ Refractory Multiple Myeloma Published: Apr 30, 2021 | […]Read More

DigiHealth

Biocon Collaborates with Voluntis on Digital Therapeutics for Insulins

Shots: The two companies collaborated to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy. The collaboration allows Biocon to offer Insulia to T2D patients across several markets globally Biocon aspires to reimagine the patient ecosystem by developing a technology-dependent operating model enabling personalization of care, thus going beyond the product […]Read More

Insights+

PharmaShots’ Key Highlights of Third Quarter 2019

The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired […]Read More

DigiHealth Regulatory

Voluntis’ Oleena Digital Application Receives FDA’s Marketing Approval to Self-Manage

Shots: The US FDA has completed its regulatory review of Oleena software which is a Class II medical device facilitating oncology-related symptoms management and remote patient monitoring Oleena is embedded with clinical algorithms offerings real-time personalized insights and actionable recommendations to the patients for managing their own symptoms while monitoring remote patients will improve clinical […]Read More